

## Product datasheet for **TL306339**

### **BTNL2 Human shRNA Plasmid Kit (Locus ID 56244)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	BTNL2 Human shRNA Plasmid Kit (Locus ID 56244)
<b>Locus ID:</b>	56244
<b>Synonyms:</b>	BTL-II; BTN7; HSBLMHC1; SS2
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>E. coli Selection:</b>	Chloramphenicol (34 ug/ml)
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Lentiviral plasmids
<b>Components:</b>	BTNL2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 56244). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
<b>RefSeq:</b>	<a href="#">NM_001304561</a> , <a href="#">NM_019602</a> , <a href="#">NM_019602.1</a> , <a href="#">BC119668</a> , <a href="#">BC127641</a> , <a href="#">BC127642</a>
<b>Summary:</b>	This gene encodes a major histocompatibility complex, class II associated, type I transmembrane protein which belongs to the butyrophilin-like B7 family of immunoregulators. It is thought to be involved in immune surveillance, serving as a negative T-cell regulator by decreasing T-cell proliferation and cytokine release. The encoded protein contains an N-terminal signal peptide, two pairs of immunoglobulin-like domains, separated by a heptad peptide sequence, and a C-terminal transmembrane domain. Naturally occurring mutations in this gene are associated with sarcoidosis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease, myositis, type 1 diabetes, systemic lupus erythematosus, acute coronary syndrome, and prostate cancer. [provided by RefSeq, May 2017]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).